Contrast Enhanced Endoscopic Ultrasound in Pancreas Lesions

• Status: Recruiting
• Trial end date: 2022-02-26
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether quantitative contrast-enhanced endoscopic ultrasound (CE-EUS) improves the evaluation of pancreas tumors and precursor lesions, including cysts, compared to conventional endoscopic ultrasound.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cedars-Sinai Medical Center
• Treatments: Pancreatin; Pancrelipase

Criteria

Inclusion Criteria:

• Patients undergoing endoscopic ultrasound for pancreatic indications

• Patients must have unexplained pancreatitis, pancreas mass(es), or pancreatic cystic lesions or worrisome clinical, imaging or laboratory findings

Exclusion Criteria:

• Patients <18 years of age, pregnant women, and lactating mothers will be excluded.

• Subjects with unstable cardiopulmonary condition will be excluded (acute myocardial infarction, acute coronary syndromes, worsening or unstable heart failure, or serious ventricular arrhythmias)

• Patients with known or suspected right-to-left, bi-directional, or transient right-to-left cardiac shunts will be excluded given theoretical (though clinically insignificant) risk of embolization

• Patients with a history of allergy to Lumason will be excluded